EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Angiotensin receptor blockers retard the progression and fibrosis via inhibiting the viability of AGTR1+ CAFs in intrahepatic cholangiocarcinoma

Jian-Hui Li, Xiao Wu, Xuhao Ni, Ya-Xiong Li, Long Xu, Xiao-Yi Hao, Wei Zhao, Xiao-Xu Zhu, Xiao-Yu Yin

Clinical and Translational Medicine · 2023-03 · 13 (3)

DOI: 10.1002/ctm2.1213 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 28.02.2023. Verfasst von Jian-Hui Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreato-Biliary Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Cancer-Associated Fibroblasts, Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal malignancy characterized by massive fibrosis and has ineffective adjuvant therapies. Here, we demonstrate the potential of angiotensin receptor blockers (ARBs) in targeting iCCA.

Methods

Masson's trichrome staining was used to assess the effect of ARBs in iCCA specimens, CCK8 and gel contraction assays in vitro and in xenograft models in vivo. RNA‐seq and ATAC‐seq were used for mechanistic investigations.

Results

Patients with iCCA who were administered ARBs had a better prognosis and a lower proportion of tumour stroma, indicating alleviated fibrosis. The presence of AGTR1, the ARBs receptor, is associated with a poor prognosis of iCCA and is highly expressed in tumour tissues and cancer‐associated fibroblasts (CAFs). The ARBs strongly attenuated the viability of AGTR1+ CAFs in vitro and retarded tumour progression and fibrosis in xenograft models of co‐cultured CAFs and iCCA cells. Still, they did not have a significant effect on AGTR1− CAFs. Moreover, ARBs decreased the secretion of AGTR1+ CAF‐derived MFAP5 via the Hippo pathway, weakened the interaction between CAFs and iCCA cells, and impaired the aggressiveness of iCCA cells by attenuating the activation of the Notch1 pathway in iCCA cells.

Conclusions

ARBs exhibit anti‐fibrotic function by inhibiting the viability of AGTR1+ CAFs. These findings support using ARBs as a novel therapeutic option for targeting iCCA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer-Associated FibroblastsCholangiocarcinomaBile Duct NeoplasmsAnimalsHumansAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsDisease Models, AnimalBile Ducts, IntrahepaticReceptor, Angiotensin, Type 1

Stichwörter der Autor:innen

AGTR1MFAP5angiotensin receptor blockerscancer-associated fibroblastsintrahepatic cholangiocarcinoma

Substanzen

Angiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAGTR1 protein, humanReceptor, Angiotensin, Type 1

Autor:innen und Institutionen

  • Department of Pancreato-Biliary Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Department of Physiology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, Guangdong, China.
  • Lau Luen Hung Private Medical Center, Unit 3 (Surgery), The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Key Laboratory of Stem Cells and Tissue Engineering, Sun Yat-sen University, Ministry of Education, Guangzhou, Guangdong, China.

Zitieren

APA

Li, J. H., Wu, X., Ni, X., Li, Y. X., Xu, L., Hao, X. Y., Zhao, W., Zhu, X. X., & Yin, X. Y. (2023). Angiotensin receptor blockers retard the progression and fibrosis via inhibiting the viability of AGTR1+ CAFs in intrahepatic cholangiocarcinoma. Clinical and Translational Medicine, 13(3). https://doi.org/10.1002/ctm2.1213

Vancouver

Li JH, Wu X, Ni X, Li YX, Xu L, Hao XY, et al. Angiotensin receptor blockers retard the progression and fibrosis via inhibiting the viability of AGTR1+ CAFs in intrahepatic cholangiocarcinoma. Clinical and Translational Medicine. 2023;13(3). doi:10.1002/ctm2.1213

BibTeX
@article{Li2023,
  author = {Li, Jian-Hui and Wu, Xiao and Ni, Xuhao and Li, Ya-Xiong and Xu, Long and Hao, Xiao-Yi and Zhao, Wei and Zhu, Xiao-Xu and Yin, Xiao-Yu},
  title = {Angiotensin receptor blockers retard the progression and fibrosis via inhibiting the viability of AGTR1+ CAFs in intrahepatic cholangiocarcinoma},
  journal = {Clinical and Translational Medicine},
  year = {2023},
  volume = {13},
  number = {3},
  doi = {10.1002/ctm2.1213}
}
Kostenlos starten →